RPC01-3204: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn,s Disease

Project: Research project

Project Details

Description

RPC01-3204: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn,s Disease
StatusActive
Effective start/end date2/1/1812/31/22

Funding

  • Celgene Corporation

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.